Investegate |Amolyt Pharma Announcements | Amolyt Pharma: Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021
Amolyt Pharma Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021 Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021 Four abstracts accepted as poster presentations for the Endocrine Society’s Annual Meeting LYON, France and NEWTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company special...
United States Ashley Robinson Amolyt Pharma Cherilyn Cecchini Lifesci Advisors Lifesci Communications
Source: investegate.co.uk